Re­al Hu­mi­ra com­pe­ti­tion may not ar­rive un­til 2026, Ab­b­Vie ex­ecs tell in­vestors

The best-sell­ing drug of all time will soon face nine com­pet­ing biosim­i­lars, with some priced as much as 86% less than the brand-name ver­sion. But Ab­b­Vie ex­ec­u­tives are con­fi­dent they’re go­ing to con­tin­ue to pro­tect their mar­ket share un­til 2025 or 2026.

When asked about Hu­mi­ra’s longer-term tail in rev­enue on to­day’s earn­ings call, Ab­b­Vie pres­i­dent and COO Rob Michael said the “tail” will “start to emerge in the 2025 or 2026 time­frame.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER